658 related articles for article (PubMed ID: 33161769)
1. Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System.
Moon J; Cohen Sedgh R; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Jan; 14(1):e007480. PubMed ID: 33161769
[TBL] [Abstract][Full Text] [Related]
2. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
3. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
[TBL] [Abstract][Full Text] [Related]
4. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
Sakaeda T; Kadoyama K; Okuno Y
PLoS One; 2011; 6(12):e28124. PubMed ID: 22205938
[TBL] [Abstract][Full Text] [Related]
5. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
Xiao M; Li L; Zhu W; Wu F; Wu B
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
[TBL] [Abstract][Full Text] [Related]
7. Adverse events with concomitant amiodarone and statin therapy.
Alsheikh-Ali AA; Karas RH
Prev Cardiol; 2005; 8(2):95-7. PubMed ID: 15860984
[TBL] [Abstract][Full Text] [Related]
8. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Alsheikh-Ali AA; Karas RH
Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
10. Statin-related adverse events: a meta-analysis.
Silva MA; Swanson AC; Gandhi PJ; Tataronis GR
Clin Ther; 2006 Jan; 28(1):26-35. PubMed ID: 16490577
[TBL] [Abstract][Full Text] [Related]
11. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs.
Akimoto H; Negishi A; Oshima S; Okita M; Numajiri S; Inoue N; Ohshima S; Kobayashi D
Pharmacol Res Perspect; 2018 Dec; 6(6):e00439. PubMed ID: 30443347
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
[TBL] [Abstract][Full Text] [Related]
13. Effect of statins on blood pressure: Analysis on adverse events released by FDA.
You T; Liu XG; Hou XD; Wang XK; Xie HH; Ding F; Yi K; Zhang P; Xie XD
Clin Exp Hypertens; 2017; 39(4):325-329. PubMed ID: 28513233
[TBL] [Abstract][Full Text] [Related]
14. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.
Penson PE; Mancini GBJ; Toth PP; Martin SS; Watts GF; Sahebkar A; Mikhailidis DP; Banach M;
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1023-1033. PubMed ID: 30311434
[TBL] [Abstract][Full Text] [Related]
15. Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries.
Chaipichit N; Krska J; Pratipanawatr T; Jarernsiripornkul N
Int J Clin Pharm; 2015 Apr; 37(2):355-64. PubMed ID: 25630895
[TBL] [Abstract][Full Text] [Related]
16. Statin-associated ocular disorders: the FDA and ADRAC data.
Mizranita V; Pratisto EH
Int J Clin Pharm; 2015 Oct; 37(5):844-50. PubMed ID: 25939673
[TBL] [Abstract][Full Text] [Related]
17. The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study.
Mueller AM; Liakoni E; Schneider C; Burkard T; Jick SS; Krähenbühl S; Meier CR; Spoendlin J
J Gen Intern Med; 2021 Sep; 36(9):2639-2647. PubMed ID: 33751411
[TBL] [Abstract][Full Text] [Related]
18. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
Rogers JR; Sarpatwari A; Desai RJ; Bohn JM; Khan NF; Kesselheim AS; Fischer MA; Gagne JJ; Connolly JG
Drug Saf; 2019 Jan; 42(1):85-93. PubMed ID: 30066315
[TBL] [Abstract][Full Text] [Related]
19. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
McAdams M; Staffa J; Dal Pan G
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
[TBL] [Abstract][Full Text] [Related]
20. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
Fujimoto M; Hosomi K; Takada M
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]